Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection
Amanda L Blackmon,1 Lauren Pinter-Brown1,2 1Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Irvine, CA, USA; 2Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA, USACorrespondence: Lauren Pinter-Brown Email lpinterb@uci.ed...
Saved in:
Main Authors: | Blackmon AL (Author), Pinter-Brown L (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A case of mogamulizumab‐induced vitiligo in a patient with mycosis fungoides
by: Charissa N. Obeng‐Nyarko, et al.
Published: (2024) -
Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sezary syndrome cutaneous T-cell lymphoma
by: Noemi Muszbek, et al.
Published: (2023) -
Overall survival in the UK in mycosis fungoides or S ´ ezary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care
by: Neil Hawkins, et al.
Published: (2023) -
Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides
by: Christina J. Walker, MD, et al.
Published: (2021) -
Mycosis Fungoides
by: Sayal S K, et al.
Published: (2001)